Updated on 2 November 2012
Venus Remedies gets first Mexican patent for antimicrobial drug, Vancoplus
New Delhi: Chandigarh-based Venus Remedies received its first patent from Mexico for Vancoplus, a novel antibiotic formulation to combat Methicillin Resistant Staphylococcus Aureus ( MRSA ) infections. The patent has been granted from the Mexico Patent office and is valid till February 2026.
Speaking on this achievement, Dr Manu Chaudhary, joint managing director and director, research, Venus Remedies, said that, "Receiving a patent grant from Mexico for our research product Vancoplus at this point in time when the frequency of MRSA strains is growing high in Mexico is a great achievement for us. Vancoplus will prove to be the best known remedy to control MRSA, VRSA (Vancomycin Resistance Staphylococcus aureus) and multi-drug resistant bacteria in a situation wherein around three-to-six percent of the population carries the community form of MRSA."
Talking about the business side, Mr Dheeraj Aggarwal, CFO, Venus Remedies, said that, "The value of the pharmaceutical markets in Latin America is at $50 billion, growing at the CAGR of approximately 15- 20 percent. Mexico being the second leading market in the region represents a growing consumer base for the drug industry as by 2020 the regional population may be as high as 687 million."
Vancoplus has the potential to restrict transfer of bacterial resistance from MRSA to other strains by preventing conjugation and transfer of plasmids containing resistant genes. Vancoplus is also the only known therapeutic option for breaking of bacterial biofilm formed by gram positive bacteria, one of the most common causes of bacterial resistance.
Vancoplus, a strategically designed formulation through CVMC technology, is the landmark achievement of Venus Medicine Research Center team. The formulation is the most effective and safe option available in the market to curb the notorious MRSA strain and multi-drug resistant microbes primarily responsible for causing various infections and Staphylococcal Endocarditis. In addition to its effectiveness in curbing infections, Vancoplus therapy also significantly reduces treatment time and cost and can be considered as empiric therapy to curb menace of MRSA. Venus Remedies is currently exporting to the various countries of LAC such as Columbia, Peru, Guatemala, Dominican Republic, Jamaica, Bahamas and the Caribbean.